Literature DB >> 32363707

Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.

Guo Liya1, Wang Yuguang1, Liu Jian1, Yuan Huaiping2, Han Xue1, Huo Jianwei1, Ma Jiaju1, Lu Youran1, Ming Chen3, Jiao Yiqing1.   

Abstract

Coronaviruses are a class of RNA viruses that can cause respiratory and intestinal infections in animals and humans. SARS-CoV, MERS-CoV, and a novel coronavirus (SARS-CoV-2 [2019-nCoV]) belong to the family Coronaviridae and the genus Betacoronavirus. At present, the understanding of SARS-CoV-2 is getting deeper and deeper. In order to better prevent and treat SARS-CoV-2, this article compares the infectivity, pathogenicity, and related clinical characteristics of the three human pathogenic coronaviruses, SARS-CoV-2, SARS-CoV, and MERS-CoV to help us further understand the pathogenic characteristics of novel coronaviruses.
© 2020 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MERS-CoV; SARS-CoV; SARS-CoV-2; clinical features; pneumonia

Mesh：

Substances：

Year:  2020        PMID： 32363707     DOI： 10.1111/apm.13047

Source DB:  PubMed          Journal:  APMIS        ISSN： 0903-4641            Impact factor:   3.205


  13 in total

Review 1.  Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.

Authors:  Reem Hoteit; Hadi M Yassine
Journal:  Vaccines (Basel)       Date:  2022-06-09

2.  Covid-19 pandemic impacts on follow-up of child growth and development.

Authors:  Gisele Nepomuceno de Andrade; Leonardo Ferreira Matoso; Tércia Moreira Ribeiro da Silva; Mark Anthony Beinner; Márcia Christina Caetano Romano; Ed Wilson Rodrigues Vieira
Journal:  Rev Saude Publica       Date:  2022-06-24       Impact factor: 2.772

Review 3.  COVID-19: Main findings after a year and half of unease and the proper scientific progress (Review).

Authors:  Marius Traian Leretter; Dan Dumitru Vulcanescu; Florin George Horhat; Anamaria Matichescu; Mircea Rivis; Laura-Cristina Rusu; Alexandra Roi; Robert Racea; Ioana Badea; Cristina Adriana Dehelean; Alexandra Mocanu; Delia Ioana Horhat
Journal:  Exp Ther Med       Date:  2022-05-04       Impact factor: 2.751

4.  Paraspinal Myositis in Patients with COVID-19 Infection.

Authors:  W A Mehan; B C Yoon; M Lang; M D Li; S Rincon; K Buch
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

Review 5.  Coronary microvascular dysfunction pathophysiology in COVID-19.

Authors:  Jie Yin; Shaoshen Wang; Yang Liu; Junhong Chen; Dongye Li; Tongda Xu
Journal:  Microcirculation       Date:  2021-06-02       Impact factor: 2.679

6.  Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.

Authors:  Juliana C Ferreira; Wael M Rabeh
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 7.  Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.

Authors:  Tolulope Joshua Ashaolu; Asad Nawaz; Noman Walayat; Ibrahim Khalifa
Journal:  Appl Microbiol Biotechnol       Date:  2021-04-19       Impact factor: 4.813

Review 8.  Infection control practices in children during COVID-19 pandemic: Differences from adults.

Authors:  İlker Devrim; Nuri Bayram
Journal:  Am J Infect Control       Date:  2020-05-26       Impact factor: 2.918

9.  Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2.

Authors:  Titilayo O Johnson; Abayomi Emmanuel Adegboyega; Opeyemi Iwaloye; Omokehinde Abiodun Eseola; Winfried Plass; Boluwatife Afolabi; Damilare Rotimi; Eman I Ahmed; Ashraf Albrakati; Gaber E Batiha; Oluyomi Stephen Adeyemi
Journal:  J Pharmacol Sci       Date:  2021-05-23       Impact factor: 3.337

Review 10.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.